Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273

Virology. 2024 Apr 8;595:110082. doi: 10.1016/j.virol.2024.110082. Online ahead of print.ABSTRACTVaccines against SARS-CoV-2 were developed during the pandemic including the BNT162b2 and the mRNA-1273. We evaluated the levels of binding antibodies against the receptor binding domain and the levels of NAbs in individuals who developed a breakthrough infection after having received three doses of mRNA-1273. A total of 51 participants were included. The breakthrough group was compared to a 1:1 matched-control group. Among the 51 individuals, 18 (35%) developed a breakthrough infection. The GMT of NAbs against the BA.1 in the BK population was 278.1 (95%CI: 168.1-324.1). This titer was significantly lower compared to the matched-control group when considering all data (GMT = 477.4; 95%CI: 316.2-541.0; p = 0.0057). Results were similar for the BA.5 (GMT = 152.0 (95%CI: 76.9-172.9) for breakthrough and 262.0 (95%CI: 171.3-301.8) for control (p = 0.0043)). Our study found that individuals receiving the mRNA-1273 booster and who developed a breakthrough infection presented lower levels of binding antibodies and NAbs before the infection as compared to a matched-control group.PMID:38636363 | DOI:10.1016/j.virol.2024.110082

Source: Virology - April 18, 2024 Category: Virology Authors: Constant Gillot Marie Tr é-Hadry Roberto Cupaiolo Laurent Blairon Alain Wilmet Ingrid Beukinga Jean-Michel Dogn é Jonathan Douxfils Julien Favresse Source Type: research